Do you want to read an article? Please log in or register.
Human epididymis protein 4 (HE4) levels inversely correlate with lung function improvement (delta FEV1) in cystic fibrosis patients receiving ivacaftor treatment
Pulmonary Fibrosis
Related content
Pulmonary Fibrosis
Effects of Lumacaftor/Ivacaftor Therapy on CFTR Function in Phe508del Homozygous Patients with Cystic Fibrosis
Am J Respir Crit Care Med.
Graeber SY, Dopfer C, Naehrlich L, Gyulumyan L, Scheuermann H, Hirtz S, Wege S, Mairbäurl H, Dorda M, Hyde R, Bagheri-Hanson A, Rueckes-Nilges C, Fischer S, Mall MA, Tümmler B
doi: 10.1164/
Pulmonary Fibrosis
SILDENAFIL IMPROVES VASCULAR ENDOTHELIAL FUNCTION IN PATIENTS WITH CYSTIC FIBROSIS
Am J Physiol Heart Circ Physiol.
Rodriguez Miguelez P, Seigler N, Tucker MA, Csanyi G, McKie KT, Forseen C, Harris RA
doi: 10.1152/ajpheart.00301.2018.
Efficacy and safety of lumacaftor and ivacaftor in patients aged 6-11 years with cystic fibrosis homozygous for F508del-CFTR: a randomised, placebo-controlled phase 3 trial
Lancet Respir Med.
Ratjen F, Hug C, Marigowda G, Tian S, Huang X, Stanojevic S, Milla CE, Robinson PD, Waltz D, Davies JC; VX14-809-109 investigator group
doi: 10.1016/
RECOMMENDED
Bronchi
Inhaled liposomal ciprofloxacin in patients with non-cystic fibrosis bronchiectasis and chronic lung infection with Pseudomonas aeruginosa (ORBIT-3 and ORBIT-4): two phase 3, randomised controlled trials
Lancet Respir Med.
Haworth CS, Bilton D, Chalmers JD, Davis AM, Froehlich J, Gonda I, Thompson B, Wanner A, O'Donnell AE
doi: 10.1016/S2213-2600(18)30427-2.
Pulmonary Fibrosis
Tezacaftor-Ivacaftor in Residual-Function Heterozygotes with Cystic Fibrosis
N Engl J Med.
Rowe SM, Daines C, Ringshausen FC, Kerem E, Wilson J, Tullis E, Nair N, Simard C, Han L, Ingenito EP, McKee C, Lekstrom-Himes J, Davies JC
doi: 10.1056/
RECOMMENDED
Pulmonary Fibrosis
Ivacaftor in cystic fibrosis with residual function: Lung function results from an N-of-1 study
★ 1
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
J Cyst Fibros.
Nick JA, St Clair C, Jones MC, Lan L, Higgins M, VX12-770-113 Study Team.
doi: 10.1016/j.jcf.2019.09.013.
First experience in Switzerland in Phe508del homozygous cystic fibrosis patients with end-stage pulmonary disease enrolled in a lumacaftor-ivacaftor therapy trial - preliminary results
Swiss Med Wkly.
Murer C, Huber LC, Kurowski T, Hirt A, Robinson CA, Bürgi U, Benden C
doi: 10.4414/smw.2018.14593.
Pulmonary Fibrosis
Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del
N Engl J Med.
Taylor-Cousar JL, Munck A, McKone EF, van der Ent CK, Moeller A, Simard C, Wang LT, Ingenito EP, McKee C, Lu Y, Lekstrom-Himes J, Elborn JS
doi: 10.1056/
RECOMMENDED
Pulmonary Fibrosis
Rapid Improvement After Starting Elexacaftor-tezacaftor-ivacaftor in Patients with Cystic Fibrosis and Advanced Pulmonary Disease
★ 3
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Am J Respir Crit Care Med
Burgel PR, Durieu I, Chiron R, Ramel S, Danner-Boucher I, Prevotat A, Grenet D, Marguet C, Reynaud-Gaubert M, Macey J, Mely L, Fanton A, Quetant S, Lemonnier L, Paillasseur JL, Da Silva J, Martin C, French Cystic Fibrosis Reference Network study group.
doi: 10.1164/rccm.202011-4153OC